MEDICAMENTS FOR INHALATION COMPRISING AN ANTICHOLINERGIC AND A BETAMIMETIC

• US 20100330186A1
• Filed: 09/03/2010
• Published: 12/30/2010
• Est. Priority Date: 07/29/2003
• Status: Abandoned Application

• Current Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: MEADE, Christopher John Montague, PAIRET, Michel, PIEPER, Michael P.
• Application Number:
  US12/875,601
• Publication Number:
  US 20100330186A1
• Time in Patent Office: Days
• US Class Current: 424/489
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/16 Amides, e.g. hydroxamic acids
• CPC Class Codes: A61K 31/46 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
• CPC Class Codes: A61K 31/4745 condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0075 for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
• CPC Class Codes: A61K 9/008 comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics

Abstract

A pharmaceutical composition comprising a compound of formula 1

wherein X⁻ is an anion with a single negative charge, and a betamimetic, optionally together with a pharmaceutically acceptable excipient, the compound of formula 1 and the betamimetic optionally in the form of their enantiomers, mixtures of their enantiomers, their racemates, their solvates, or their hydrates, processes for preparing them, and their use in the treatment of respiratory tract diseases.

Claims

1. A pharmaceutical composition comprising:

(a) a compound of formula 1

2. The pharmaceutical composition of claim 1, further comprising a pharmaceutically acceptable excipient.

3. The pharmaceutical composition of claim 1, wherein X⁻

is fluoride, chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate, or p-toluenesulfonate.

5. The pharmaceutical composition of claim 1, wherein the formoterol is a formoterol salt selected from sodium salts, sulfobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogen phosphates, palmitates, pivalates, or furoates, or mixtures thereof.

6. The pharmaceutical composition of claim 1, wherein formoterol is a formoterol salt selected from hydrochloride, sulfate or fumarate.

8. The pharmaceutical composition of claim 1, wherein the weight ratio of the compound of formula 1 to formoterol are in a range from about 1:

5 to 500;

1.

9. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is suitable for inhalation.

10. The pharmaceutical composition according to claim 1, wherein the compound of formula 1 is an enantiomer of formula 1-en

11. The pharmaceutical composition according to claim 9, wherein the compound of formula 1 is an enantiomer of formula 1-en

12. The pharmaceutical composition according to claim 9, wherein the pharmaceutical composition is an inhalable powder, a propellant-containing metering aerosol, or a propellant-free inhalable solution or suspension.

14. The pharmaceutical composition according to claim 2, wherein the pharmaceutical composition further comprises a suitable physiologically acceptable excipient selected from the group consisting of:

monosaccharides, disaccharides, oligo- and polysaccharides, polyalcohols, and salts.

16. The pharmaceutical composition of claim 14, wherein the excipient has a maximum average particle size of up to 250 μ

m.

18. The pharmaceutical composition of claim 16, wherein the excipient has a maximum average particle size of between 10 μ

m and 150 μ

m.

19. A capsule containing a pharmaceutical composition according to claim 1, in the form of an inhalable powder.

20. A capsule containing a pharmaceutical composition according to claim 10 in the form of an inhalable powder.

21. A pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a propellant-containing inhalable aerosol and the compound of formula 1 and the formoterol are in dissolved or dispersed form.

22. The pharmaceutical composition according to claim 21, wherein the propellant-containing inhalable aerosol comprises a propellant gas selected from hydrocarbons and halohydrocarbons.

23. The pharmaceutical composition according to claim 21, wherein the propellant-containing inhalable aerosol comprises a propellant gas selected from the group consisting of:

n-propane;

n-butane;

isobutane; and

chlorinated and/or fluorinated derivatives of methane, ethane, propane, butane, cyclopropane, and cyclobutane.

24. The pharmaceutical composition according to claim 22, wherein the propellant gas is TG134a, TG227, or a mixture thereof.

25. The pharmaceutical composition according to claim 21, further comprising at least one of a cosolvent, stabilizer, surfactant, antioxidant, lubricant, or means for adjusting the pH of the composition.

26. The pharmaceutical composition according to claim 22, further comprising at least one of a cosolvent, stabilizer, surfactant, antioxidant, lubricant, or means for adjusting the pH of the composition.

27. The pharmaceutical composition according to claim 21, wherein the amount of the compound of formula 1′

or the formoterol is up to 5 wt. % of the pharmaceutical composition.

28. A pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is propellant-free inhalable solution or suspension that further comprises a solvent selected from water, ethanol, or a mixture of water and ethanol.

29. The pharmaceutical composition according to claim 28, wherein the pH is between 2 and 7.

30. The pharmaceutical composition according to claim 29, wherein the pH is between 2 and 5.

31. The pharmaceutical composition according to claim 28, wherein the pH of the pharmaceutical composition is adjusted by means of one or more acids selected from the group consisting of:

hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid, and propionic acid.

32. The pharmaceutical composition according to claim 28, further comprising other cosolvents or excipients.

33. The pharmaceutical composition according to claim 31, further comprising other cosolvents or excipients.

34. The pharmaceutical composition according to claim 32, wherein the composition contains a cosolvent is selected from the group consisting of alcohols, glycols, polyoxyethylene alcohols, and polyoxyethylene fatty acid esters.

35. The pharmaceutical composition according to claim 32, wherein the composition contains a cosolvent is selected from the group consisting of:

isopropyl alcohol, propylene glycol, polyethylene glycol, polypropylene glycol, glycol ether, and glycerol.

36. The pharmaceutical composition according to claim 32, wherein the composition contains an excipient is selected from the group consisting of:

surfactants, stabilizers, complexing agents, antioxidants, preservatives, flavorings, pharmacologically acceptable salts, and vitamins.

37. The pharmaceutical composition according to claim 36, wherein the composition contains an excipient is selected from the group consisting of:

edetic acid, a salt of edetic acid, ascorbic acid, vitamin A, vitamin E, tocopherols, cetyl pyridinium chloride, benzalkonium chloride, benzoic acid, and benzoate salts.

42. A method of treating COPD or asthma in a patient in need of such treatment, the method comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition according to claim 1.

47. The pharmaceutical composition of claim 1, wherein the component (b) is a formoterol salt, wherein the formoterol salt is formoterol fumerate or a dihydrate of formoterol fumerate.

48. The pharmaceutical composition of claim 1, wherein X⁻

is bromide.

49. The pharmaceutical composition of claim 1, wherein the compound of formula 1 and formoterol in a ratio by weight ranging from 1:

5 to 500;

1.

50. The pharmaceutical composition of claim 1, wherein the compound of formula 1 and formoterol in a ratio by weight ranging from 1:

5 to 200;

1.

51. The pharmaceutical composition of claim 1, wherein the compound of formula 1 and formoterol in a ratio by weight ranging from 1:

2 to 100;

1.

4. (canceled)

7. (canceled)

13. (canceled)

15. (canceled)

17. (canceled)

38. A pharmaceutical composition consisting essentially of:

(a) a compound of formula 1

39. A pharmaceutical composition consisting essentially of:

(a) a compound of formula 1

40. A pharmaceutical composition consisting essentially of:

(a) a compound of formula 1-en

41. A pharmaceutical composition consisting essentially of:

(a) a compound of formula 1-en

43. A kit comprising one or more unit dosage containers containing a pharmaceutical composition, each unit dosage container containing a pharmaceutical composition comprising:

(a) a compound of formula 1

44. The kit according to claim 43, further comprising instructions with directions for using the kit.

45. A kit comprising:

(a) a first container containing a first pharmaceutical formulation comprising a compound of formula 1

46. The kit according to claim 45, further comprising instructions with directions for using the kit.